SG11201407400XA - V1a receptor agonists - Google Patents
V1a receptor agonistsInfo
- Publication number
- SG11201407400XA SG11201407400XA SG11201407400XA SG11201407400XA SG11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- llll
- california
- pct
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010003445 Ascites Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101100177642 Rattus norvegicus Hgs gene Proteins 0.000 abstract 1
- 101100129853 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SRB2 gene Proteins 0.000 abstract 1
- 244000204900 Talipariti tiliaceum Species 0.000 abstract 1
- 229940083335 Vasopressin agonist Drugs 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 206010034674 peritonitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polyurethanes Or Polyureas (AREA)
- Polyesters Or Polycarbonates (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645558P | 2012-05-10 | 2012-05-10 | |
| PCT/US2013/040414 WO2013170077A2 (en) | 2012-05-10 | 2013-05-09 | V1a receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407400XA true SG11201407400XA (en) | 2014-12-30 |
Family
ID=48652296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407400XA SG11201407400XA (en) | 2012-05-10 | 2013-05-09 | V1a receptor agonists |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9644000B2 (sr) |
| EP (1) | EP2847210B1 (sr) |
| JP (1) | JP6231554B2 (sr) |
| KR (1) | KR102050356B1 (sr) |
| CN (1) | CN104350065B (sr) |
| AR (1) | AR091013A1 (sr) |
| AU (1) | AU2013259393B2 (sr) |
| BR (1) | BR112014027996B1 (sr) |
| CA (1) | CA2871776C (sr) |
| DK (1) | DK2847210T3 (sr) |
| ES (1) | ES2571928T3 (sr) |
| HR (1) | HRP20160468T1 (sr) |
| HU (1) | HUE027519T2 (sr) |
| IL (1) | IL235558A (sr) |
| JO (1) | JO3109B1 (sr) |
| MX (1) | MX353864B (sr) |
| MY (1) | MY167248A (sr) |
| NZ (1) | NZ701365A (sr) |
| PH (1) | PH12014502510A1 (sr) |
| PL (1) | PL2847210T3 (sr) |
| RS (1) | RS54722B1 (sr) |
| RU (1) | RU2634617C2 (sr) |
| SA (1) | SA113340536B1 (sr) |
| SG (1) | SG11201407400XA (sr) |
| SI (1) | SI2847210T1 (sr) |
| TW (1) | TWI632161B (sr) |
| WO (1) | WO2013170077A2 (sr) |
| ZA (1) | ZA201408172B (sr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9388214B2 (en) | 2014-11-05 | 2016-07-12 | Ferring B.V. | V1A receptor agonists |
| JP2017014206A (ja) * | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス,インコーポレイテッド | 腹水の治療 |
| US11021514B2 (en) | 2016-06-01 | 2021-06-01 | Athira Pharma, Inc. | Compounds |
| CN109010795B (zh) * | 2018-09-12 | 2021-10-22 | 南京康舟医药科技有限公司 | 醋酸特利加压素注射液以及其制备方法 |
| AU2020279395B2 (en) | 2019-05-22 | 2025-08-28 | Biovie Inc. | Formulations of terlipressin |
| PH12023550152A1 (en) * | 2020-07-17 | 2024-03-18 | Pharmain Corp | V1a receptor partial agonist and method of use |
| WO2023183339A1 (en) * | 2022-03-22 | 2023-09-28 | Ocelot Bio, Inc. | Selective vasopressin receptor agonist for end-stage liver disease |
| CN120265305A (zh) * | 2022-09-30 | 2025-07-04 | 辉凌公司 | 治疗终末期肝病及其相关并发症的混合型血管加压素受体激动剂-拮抗剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003513082A (ja) * | 1999-11-04 | 2003-04-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | バソプレッシン拮抗物質としての非ペプチド置換されたベンゾチアゼピン類 |
| EP1188443A1 (en) * | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| JO2937B1 (en) * | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Tight muscles of the peptide vascular tensioner receptor |
| CA2615726C (en) * | 2005-07-14 | 2014-05-27 | Caterina Bissantz | Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists |
| KR101018934B1 (ko) * | 2005-09-28 | 2011-03-02 | 에프. 호프만-라 로슈 아게 | 바소프레신 수용체 길항물질로서인돌-3-일-카보닐-아자스피로 유도체 |
| DK1984012T3 (en) * | 2006-02-13 | 2016-03-29 | Ferring Bv | USE OF peptidic vasopressin receptor agonists |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
-
2013
- 2013-04-24 JO JOP/2013/0118A patent/JO3109B1/ar active
- 2013-04-30 TW TW102115416A patent/TWI632161B/zh active
- 2013-05-08 SA SA113340536A patent/SA113340536B1/ar unknown
- 2013-05-09 WO PCT/US2013/040414 patent/WO2013170077A2/en not_active Ceased
- 2013-05-09 KR KR1020147034501A patent/KR102050356B1/ko active Active
- 2013-05-09 SG SG11201407400XA patent/SG11201407400XA/en unknown
- 2013-05-09 RU RU2014143941A patent/RU2634617C2/ru active
- 2013-05-09 SI SI201330175A patent/SI2847210T1/sl unknown
- 2013-05-09 BR BR112014027996-9A patent/BR112014027996B1/pt active IP Right Grant
- 2013-05-09 ES ES13729826T patent/ES2571928T3/es active Active
- 2013-05-09 NZ NZ701365A patent/NZ701365A/en unknown
- 2013-05-09 DK DK13729826.1T patent/DK2847210T3/en active
- 2013-05-09 PL PL13729826T patent/PL2847210T3/pl unknown
- 2013-05-09 JP JP2015511718A patent/JP6231554B2/ja active Active
- 2013-05-09 US US14/400,282 patent/US9644000B2/en active Active
- 2013-05-09 MY MYPI2014703280A patent/MY167248A/en unknown
- 2013-05-09 HR HRP20160468TT patent/HRP20160468T1/hr unknown
- 2013-05-09 EP EP13729826.1A patent/EP2847210B1/en active Active
- 2013-05-09 MX MX2014013646A patent/MX353864B/es active IP Right Grant
- 2013-05-09 AU AU2013259393A patent/AU2013259393B2/en active Active
- 2013-05-09 RS RS20160293A patent/RS54722B1/sr unknown
- 2013-05-09 CA CA2871776A patent/CA2871776C/en active Active
- 2013-05-09 CN CN201380024444.2A patent/CN104350065B/zh active Active
- 2013-05-09 HU HUE13729826A patent/HUE027519T2/en unknown
- 2013-05-10 AR ARP130101626 patent/AR091013A1/es active IP Right Grant
-
2014
- 2014-11-06 IL IL235558A patent/IL235558A/en active IP Right Grant
- 2014-11-07 ZA ZA2014/08172A patent/ZA201408172B/en unknown
- 2014-11-10 PH PH12014502510A patent/PH12014502510A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407400XA (en) | V1a receptor agonists | |
| SG11201808625QA (en) | SOLUBLE C5aR ANTAGONISTS | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201407381VA (en) | System and methods for coping with doppler effects in distributed-input distributed-output wireless systems | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| SG11201808163WA (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201408721RA (en) | Method and apparatus for encoding video and method and apparatus for decoding video determining inter-prediction reference picture list depending on block size | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201407773VA (en) | Gypsum-based building products and method for the manufacture thereof | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |